Steminent Biotherapeutics Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • IPO Registration

  • Employees
  • 57

Employees

  • Latest Deal Type
  • IPO
  • (Announced)

  • Investors
  • 6

Steminent Biotherapeutics General Information

Description

Steminent Biotherapeutics Inc is a international stem cell biopharmaceutical company which has stable and efficient stem cell platform technology, aiming to develop live cell drugs to treat degenerative diseases as well as acute and life-threatening diseases. With its Stemchymal which is proprietary technology platform generating the standardized, clinical grade, allogeneic stem cells isolated from human adipose tissue. It is operated in strict compliance to regulations of Taiwan.

Contact Information

Ownership Status
In IPO Registration
Financing Status
Venture Capital-Backed
Corporate Office
  • 4F-1, No. 12, Wenhu Street
  • Neihu District
  • Taipei, 114
  • Taiwan
+886 02
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 4F-1, No. 12, Wenhu Street
  • Neihu District
  • Taipei, 114
  • Taiwan
+886 02

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Steminent Biotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. IPO 02-Sep-2026 Announced Generating Revenue
4. Later Stage VC 31-Aug-2023 Completed Generating Revenue
3. Corporate Completed Generating Revenue
2. Corporate 12-Oct-2021 $800K $1.7M Completed Generating Revenue
1. Corporate 01-Jul-2017 $901K $901K Completed Generating Revenue
To view Steminent Biotherapeutics’s complete valuation and funding history, request access »

Steminent Biotherapeutics Patents

Steminent Biotherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023902528-A0 Modified mesenchymal stem cells and uses thereof Pending 10-Aug-2023
AU-2024273709-A1 Methods for treating polyq disease and novel adipose tissue derived mesenchymal stem cells Pending 15-May-2023
EP-4712989-A1 Methods for treating polyq disease and novel adipose tissue derived mesenchymal stem cells Pending 15-May-2023
US-20260284117-A1 Methods for treating polyq disease and novel adipose tissue derived mesenchymal stem cells Pending 15-May-2023
WO-2024235265-A1 Methods for treating polyq disease and novel adipose tissue derived mesenchymal stem cells Inactive 15-May-2023 A61K35/28
To view Steminent Biotherapeutics’s complete patent history, request access »

Steminent Biotherapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Steminent Biotherapeutics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Daiwa Corporate Investment Venture Capital Minority
First Financial Holding Corporation Minority
Top Taiwan Venture Capital Group Venture Capital Minority
ReproCELL Corporation Minority
Giddi Pharma Company Corporation Minority
You’re viewing 5 of 6 investors. Get the full list »

Steminent Biotherapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Steminent Biotherapeutics’s complete esg history, request access »

Steminent Biotherapeutics FAQs

  • When was Steminent Biotherapeutics founded?

    Steminent Biotherapeutics was founded in 2007.

  • Where is Steminent Biotherapeutics headquartered?

    Steminent Biotherapeutics is headquartered in Taipei, Taiwan.

  • What is the size of Steminent Biotherapeutics?

    Steminent Biotherapeutics has 57 total employees.

  • What industry is Steminent Biotherapeutics in?

    Steminent Biotherapeutics’s primary industry is Biotechnology.

  • Is Steminent Biotherapeutics a private or public company?

    Steminent Biotherapeutics is a Private company.

  • What is Steminent Biotherapeutics’s current revenue?

    The current revenue for Steminent Biotherapeutics is .

  • How much funding has Steminent Biotherapeutics raised over time?

    Steminent Biotherapeutics has raised $15.8M.

  • Who are Steminent Biotherapeutics’s investors?

    Daiwa Corporate Investment, First Financial Holding, Top Taiwan Venture Capital Group, ReproCELL, and Giddi Pharma Company are 5 of 6 investors who have invested in Steminent Biotherapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process